AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer

Peking Union Medical College

Status: Completed

Conditions: Lung Metastases; Colorectal Cancer

Treatments: Other: The location of the patient's treatment

Study type: Observational

Funder types: Other

Identifiers

NCT05816902

PekingUMC02

Details and patient eligibility

About

Background:

To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients.

Method:

The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.

Enrollment: 2,779 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with pathologic confirmation of a primary CRC diagnosis

Exclusion criteria

• (1) patients with multiple primary cancers or other malignancies; (2) patients identified via autopsy or death certificate; and (3) patients with uncertain clinical data values

Trial design

2,779 participants in 2 patient groups

validation set 1

Description:

The validation set 1 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.

Treatment:

Other: The location of the patient's treatment

validation set 2

Description:

The validation set 2 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Second Affiliated Hospital of Harbin Medical University.

Treatment:

Other: The location of the patient's treatment